Clinical Trials Sponsored by NeoTherapeutics

Total 393 results

NeoTherapeutics

Completed

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

Peripheral Nervous System Diseases | Chemotherapy-Induced Peripheral Neuropathy

United States
Oncotherapeutics

Not yet recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Oncotherapeutics

Not yet recruiting

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Oncotherapeutics

Terminated

Combination Study for High Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Barinthus Biotherapeutics

Not yet recruiting

VTP-1000 in Adults With Celiac Disease

Celiac Disease
Fore Biotherapeutics

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations

United States, Germany, Spain, United Kingdom, Korea, Republic of, Italy, France, Sweden, Canada
Sonnet BioTherapeutics

Recruiting

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Tavotek Biotherapeutics

Active, not recruiting

Study of TAVO101 in Healthy Volunteers

Healthy Subjects

Australia
Tavotek Biotherapeutics

Completed

Study of TAVO103A in Healthy Volunteers

Healthy Subjects

United States
Oncotherapeutics
Amgen

Terminated

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Multiple Myeloma

United States
Revolo Biotherapeutics

Completed

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Revolo Biotherapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Healthy Volunteer

United States
Sonnet BioTherapeutics

Completed

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Healthy Adult

Australia
Aeglea Biotherapeutics

Terminated

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Homocystinuria Due to Cystathionine Beta-Synthase Deficiency

United States, United Kingdom, Australia
Atara Biotherapeutics

No longer available

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Fore Biotherapeutics

Completed

NovellusDx Tissue Collection Protocol

Patients That Have Been Diagnosed With Colorectal Cancer | Patients Eligible for Tumor Biopsy

Israel
Eleven Biotherapeutics

Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Diabetic Macular Edema
Eleven Biotherapeutics

Unknown

Study of EBI-005 in Dry Eye Disease (DED) (EBI-005)

Dry Eye

United States
Oncotherapeutics
Cephalon

Completed

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

Fatigue | Multiple Myeloma

United States
Tavotek Biotherapeutics

Recruiting

A Study of TAVO412 in Patients With Cancer (TAVO412)

Cancer

United States
Excision BioTherapeutics

Recruiting

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

HIV-1-infection

United States
Sonnet BioTherapeutics

Terminated

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Australia
Fore Biotherapeutics

Active, not recruiting

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Advanced Unresectable Solid Tumors | BRAF-mutated Tumors

United States
Alethia Biotherapeutics

Completed

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

NSCLC Stage IV

United States, Canada
Atara Biotherapeutics

Terminated

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (EMBOLD)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States, Australia, Canada
Excision BioTherapeutics

Enrolling by invitation

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

HIV-1-infection

United States
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States
Aeglea Biotherapeutics

Terminated

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

Canada
Aeglea Biotherapeutics

Completed

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102)

Arginase I Deficiency | Hyperargininemia

United States, Canada, United Kingdom, Portugal
Aeglea Biotherapeutics

Completed

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

United States, Italy, Canada, France, United Kingdom, Austria, Germany
Revolo Biotherapeutics

Completed

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United Kingdom
Revolo Biotherapeutics

Completed

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Healthy Volunteer

United Kingdom
Fore Biotherapeutics

Terminated

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Melanoma | Colorectal Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Histiocytosis | Thyroid Cancer | Hairy Cell Leukemia

United States
Gemstone Biotherapeutics

Unknown

Briagen Observational Study (BOS)

Mohs Surgery

United States
Aeglea Biotherapeutics

Completed

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Arginase I Deficiency | Hyperargininemia

United States, Canada, United Kingdom, Portugal
Atara Biotherapeutics

No longer available

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

CMV Viremia | CMV Disease
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
BrightPath Biotherapeutics

Completed

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Melanoma

United States
Pinta Biotherapeutics

Completed

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

End Stage Renal Disease | Kidney Disease | Protein Energy Wasting

United States
Fore Biotherapeutics

Completed

NovellusDx Cancer Early Detection Blood Test- Clinical Trial

Lung Cancer

Israel
Oncotherapeutics
Amgen

Completed

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Multiple Myeloma

United States
Oncotherapeutics
Amgen

Unknown

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

Multiple Myeloma

United States
Northwest Biotherapeutics

Available

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (DCVax-L EAP)

Glioblastoma Multiforme | GBM

United States
Eleven Biotherapeutics

Completed

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis (EBI-005-AC-2)

Allergic Conjunctivitis (AC)

United States
Northwest Biotherapeutics

Unknown

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Melanoma | Colorectal Cancer | Pancreatic Cancer | Liver Cancer | Locally Advanced Tumor | Metastatic Solid Tissue Tumors

United States
Jennerex Biotherapeutics

Completed

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE)

HCC | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, United States, Hong Kong, Canada, Germany, France, Taiwan
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Melanoma

United States
Fore Biotherapeutics

Not yet recruiting

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.

Healthy Volunteer

United States

Clinical Trials Sponsored by NeoTherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations